Purchase and availability checkTesamorelin in the United States
Can you buy Tesamorelin in the United States?
This page does not establish a legitimate retail purchase from the compound name or an online listing alone. EGRIFTA WR is an FDA-licensed tesamorelin prescription product under BLA 022505, with an 11.6 mg presentation and a defined HIV-lipodystrophy indication.
Compare current Tesamorelin research listings for United States.
This exact seller page states United States market coverage. It is dated catalog observations, not proof of legal supply, contents, safety, or medical suitability.
Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.
01
Can you buy Tesamorelin in the United States?
This page does not establish a legitimate retail purchase from the compound name or an online listing alone. EGRIFTA WR is an FDA-licensed tesamorelin prescription product under BLA 022505, with an 11.6 mg presentation and a defined HIV-lipodystrophy indication. The 10 mg research listings tracked here are not EGRIFTA WR, do not share its label, and do not inherit its approval or supply chain. Before acting on an offer, match the exact product, authorization, seller identity, and supply route in the official records below.
02
Which official records should be checked for Tesamorelin in United States?
Resolve the exact identity of Tesamorelin through Check the FDA Purple Book product record from U.S. Food and Drug Administration. Then search Drugs@FDA approved drug database from U.S. Food and Drug Administration for the destination product record and Locate a state-licensed online pharmacy from U.S. Food and Drug Administration for the seller, establishment, or supply route in United States. A match in one record does not replace the other two checks.
03
Does an online listing prove Tesamorelin is authorized or available in United States?
No. A page using the name Tesamorelin, local currency, a domestic delivery claim, or a familiar package image is only a lead. This record resolves seller-labelled 10 mg tesamorelin research listings. EGRIFTA WR is a separate FDA-licensed prescription product with a specific application, 11.6 mg presentation, indication, label, and regulated supply chain. The research listings do not inherit that approval. For United States, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.
Continue the exact comparison
Related country and compound records.
Compare another tracked name in United States, or keep Tesamorelin fixed and change the destination within North America. The identity, product, and seller checks remain separate.
EGRIFTA WR is an FDA-licensed tesamorelin prescription product under BLA 022505, with an 11.6 mg presentation and a defined HIV-lipodystrophy indication. The 10 mg research listings tracked here are not EGRIFTA WR, do not share its label, and do not inherit its approval or supply chain.
A credible result must keep these separate. The official links answer different questions and should be checked in sequence.
Check the FDA Purple Book product record
Check the FDA Purple Book product record is maintained by U.S. Food and Drug Administration. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Drugs@FDA approved drug database is maintained by U.S. Food and Drug Administration. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Locate a state-licensed online pharmacy is maintained by U.S. Food and Drug Administration. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
A US peptide search can surface prescription drugs, compounded preparations, telehealth offers, and laboratory-research materials in one result set. Federal and state records answer different questions, so no single lookup validates every route.
FDA’s BeSafeRx directory sends consumers to each state board’s pharmacy-license database and says an unlisted online pharmacy should not be used.
Sections 503A and 503B apply different conditions to compounding from bulk drug substances; FDA updates the underlying lists and policies as substances are evaluated.
FDA’s peptide-related bulk-substance page identifies limited information or potential safety concerns for several names that also appear in research and wellness marketing.
Destination checklist
Repeat the country checks before comparing any offer.
The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.
01
Start with the seller class
For an online pharmacy claim, use FDA’s state-license directory to reach the relevant board database and match the business, address, and current license before comparing price.
02
Separate the federal record
Check FDA approval, shortage, outsourcing-facility, and bulk-substance records separately; a state pharmacy license does not make every product or compounding claim federally supported.
03
Keep research outside care
A laboratory-research listing is not a prescription pathway. Compare only like-for-like catalog rows and retain the research-only boundary, source date, shipping claim, and evidence-access label.
Primary evidence
Audit every source used by this page.
Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.
Compare another tracked name in United States, or keep Tesamorelin fixed and change the destination within North America. The identity, product, and seller checks remain separate.
